Transgene has employed a novel gene silencing (within RNAi platform) technology to develop this drug.
The technology involves highly selective knock-down of specific liver cancer producing gene targets, which has demonstrated remarkable regression of the tumours in the animal studies, said the company.
Unlike Transgene’s new hepatic cancer drug, traditional drugs used in cancer chemotherapy are non-selective, and induce DNA damage leading to tumor relapse.
Transgene has been involved in the development of technology for different bio-pharmaceuticals, recombinant vaccines and therapeutics.